Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery

Summary

This randomized phase II trial studies how well erlotinib hydrochloride works in treating patients with bladder cancer undergoing surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2014-10-01

Primary completion

2018-03-30

Completion

2018-03-30

Outcome

Missed primary endpoint

registry analysis (other test); Group I (Erlotinib Hydrochloride) vs Group II (Placebo); p = 0.208; Wilcoxon rank-sum test NCT02169284 ↗

Publications

• Downs TM, Bailey HH, Lozar T, Schmitz NS, Green H, Scarlett CO, Havighurst TC, Twaroski K, DeShong K, Wollmer B, Bivalacqua TJ, Saltzstein DR, Shore N, Kim K, Huang W, Ricke WA, Barroilhet L, House M, Parnes HL, Messing E. Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery. Cancer Prev Res (Phila). 2025 Jan 6;18(1):31-39. doi: 10.1158/1940-6207.CAPR-24-0194.

Drugs

Indications